Clinical outcome assessment trends in clinical trials—Contrasting oncology and non‐oncology trials
Cancer Medicine · 2023-08 · 12 (16) · 16945-16957
DOI: 10.1002/cam4.6325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 08.07.2023. Verfasst von Yeonju Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Background
Clinical outcome assessments (COAs) are key to patient‐centered evaluation of novel interventions and supportive care. COAs are particularly informative in oncology where a focus on how patients feel and function is paramount, but their incorporation in trial outcomes have lagged that of traditional survival and tumor responses. To understand the trends of COA use in oncology and the impact of landmark efforts to promote COA use, we computationally surveyed oncology clinical trials in ClinicalTrials.gov comparing them to the rest of the clinical research landscape.
Methods
Oncology trials were identified using medical subject heading neoplasm terms. Trials were searched for COA instrument names obtained from PROQOLID. Regression analyses assessed chronological and design‐related trends.
Results
Eighteen percent of oncology interventional trials initiated 1985–2020 ( N = 35,415) reported using one or more of 655 COA instruments. Eighty‐four percent of the COA‐using trials utilized patient‐reported outcomes, with other COA categories used in 4–27% of these trials. Likelihood of COA use increased with progressing trial phase (OR = 1.30, p < 0.001), randomization (OR = 2.32, p < 0.001), use of data monitoring committees (OR = 1.26, p < 0.001), study of non‐FDA‐regulated interventions (OR = 1.23, p = 0.001), and in supportive care versus treatment‐focused trials (OR = 2.94, p < 0.001). Twenty‐six percent of non‐oncology trials initiated 1985–2020 ( N = 244,440) reported COA use; they had similar COA‐use predictive factors as oncology trials. COA use increased linearly over time ( R = 0.98, p < 0.001), with significant increases following several individual regulatory events.
Conclusion
While COA use across clinical research has increased over time, there remains a need to further promote COA use particularly in early phase and treatment‐focused oncology trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Yeonju Kim, Orieta Celiku
Förderung
- National Cancer Institute
Zitieren
APA
Kim, Y., Gilbert, M. R., Armstrong, T. S., & Celiku, O. (2023). Clinical outcome assessment trends in clinical trials—Contrasting oncology and non‐oncology trials. Cancer Medicine, 12(16), 16945-16957. https://doi.org/10.1002/cam4.6325
Vancouver
Kim Y, Gilbert MR, Armstrong TS, Celiku O. Clinical outcome assessment trends in clinical trials—Contrasting oncology and non‐oncology trials. Cancer Medicine. 2023;12(16):16945-16957. doi:10.1002/cam4.6325
BibTeX
@article{Kim2023,
author = {Kim, Yeonju and Gilbert, Mark R and Armstrong, Terri S and Celiku, Orieta},
title = {Clinical outcome assessment trends in clinical trials—Contrasting oncology and non‐oncology trials},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {16},
pages = {16945--16957},
doi = {10.1002/cam4.6325}
}
EUVIMED